Workflow
ChemPartner(300149)
icon
Search documents
睿智医药:关于持股5%以上股东部分股份质押的公告
2023-08-15 09:25
证券代码:300149 证券简称:睿智医药 公告编号:2023-37 睿智医药科技股份有限公司 睿智医药科技股份有限公司(以下简称"公司")近日接到公司持股5%以上 股东上海睿昀企业管理中心(有限合伙)(以下简称"上海睿昀")的通知,上 海睿昀将其持有的公司部分股份办理了质押,具体事项如下: 二、股东股份累计质押情况 截至本公告日,上述股东股份累计质押情况如下: | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 情况 | | 情况 | | | | | | 本次质押 | 本次质押 | 占其所 | 占公 | 已质押股 | | 未质押 | | | 股东 | 持股数量 | 持股 | 前质押股 | 后质押股 | 持股份 | 司总 | 份限售和 | 占已 | 股份限 | 占未 | | 名称 | (股) | 比例 | 份数量 | 份数量 | | 股本 | | 质押 | | 质押 | | | | | (股) | (股) | 比例 | | ...
睿智医药(300149) - 睿智医药2023年7月12日投资者关系活动记录表
2023-07-13 09:54
Group 1: Company Overview and Management Changes - The company has updated its executive team to enhance management professionalism by hiring experienced professionals and promoting existing scientists to senior management positions [1] - Organizational restructuring has been implemented to redefine business segments, focusing on cost reduction and efficiency improvements in the chemical business due to intense market competition [1] Group 2: Business Segment Performance - The pharmacology and pharmacokinetics segments show strong profitability, with ongoing investments in R&D and market expansion to increase revenue [1] - The biopharmaceutical segment needs to overcome market challenges and is focusing on new business development while managing existing operations [2] Group 3: Internal Management and Strategy - The company is concentrating on internal fine management, including digital and intelligent process management to enhance precision and efficiency [2] - A major client strategy is being implemented to expand both domestic and international markets, thereby increasing industry competitiveness [2] Group 4: Business Development and Market Conditions - The company’s business operations are stable, with no significant impact from recent industry policies or geopolitical factors [2] - The BD team currently consists of 20 members, with no immediate plans for expansion, but future growth will align with business needs [2] Group 5: Employee Retention and Future Outlook - High employee retention is attributed to favorable work environment, corporate culture, growth opportunities, and comprehensive training systems [3] - The company anticipates that the innovative drug market will present new opportunities despite current capital challenges, focusing on internal adjustments and proactive planning for future growth [3]
睿智医药:睿智医药业绩说明会、路演活动信息
2023-05-23 10:21
4.国外实验猴价格上涨了好多。我想问一下国内情况如何?公司在这方 面是否有优势,然后在优势之上获取更多的订单? 答:投资者您好,国内的价格没有明显的波动,相关事件暂时未对公司 的业务产生明显影响。 证券代码:300149 证券简称:睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 编号:2023-02 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 睿智医药 年度业绩说明会采用网络远程方式进行,面向全体投资者 2022 | | 人员姓名 | | | 时间 | 2023 年 5 月 23 日 15:00-17:00 | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 | | 公司接待人员姓 | 睿智医药董事、首席执行官:张继国 | | 名 | 睿智医药独立董事:杨凌 | | | 睿智医药首席财务官:王奎 | | | 睿智医药董事会秘书:许剑 | | | 1.公司在上海临港小分 ...
睿智医药:关于举行2022年度网上业绩说明会的公告
2023-05-12 09:36
证券代码:300149 证券简称:睿智医药 公告编号:2023-31 睿智医药科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 出席本次说明会的人员有:公司董事、首席执行官张继国先生,首席财务官 王奎先生,独立董事杨凌先生,董事会秘书许剑先生。 为充分尊重投资者、提升交流效率及针对性,现就公司本次说明会提前向投 资者公开征集问题。投资者可提前登录"互动易"平台(http://irm.cninfo.com.cn) "云访谈"栏目,进入公司 2022 年度业绩说明会页面进行提问,公司将在本次 说明会上对投资者普遍关注的问题进行交流回答。欢迎广大投资者积极参与本次 说明会。 特此公告。 睿智医药科技股份有限公司 董事会 2023 年 5 月 12 日 睿智医药科技股份有限公司(以下简称"公司")于 2023 年 4 月 27 日在中国 证监会指定的创业板信息披露媒体披露了《2022 年年度报告》及其摘要。为了 让广大投资者能进一步了解公司 2022 年年度报告和经营情况,加强公司与投资 者的沟通互动,公司将于 ...
睿智医药(300149) - 2022 Q4 - 年度财报
2023-04-26 16:00
Financial Performance - The company's operating revenue for 2022 was ¥1,326,584,320.12, a decrease of 21.54% compared to ¥1,690,677,943.33 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥378,585,006.97, a significant increase of 194.12% from a loss of ¥402,245,074.78 in 2021[25]. - The net cash flow from operating activities for 2022 was ¥262,460,386.22, down 30.61% from ¥378,219,891.25 in 2021[25]. - The total assets at the end of 2022 were ¥3,823,897,141.71, a decrease of 9.33% from ¥4,217,591,526.68 at the end of 2021[25]. - The company's basic earnings per share for 2022 was ¥0.76, compared to a loss of ¥0.81 in 2021, marking a 193.83% improvement[25]. - The weighted average return on equity for 2022 was 17.52%, an increase of 35.92% from -18.40% in 2021[25]. - The total revenue for 2022 was approximately ¥1.33 billion, a decrease of 21.54% compared to ¥1.69 billion in 2021[66]. - The revenue from pharmaceutical R&D services and production outsourcing was approximately ¥1.19 billion, accounting for 89.37% of total revenue, down 12.38% from ¥1.35 billion in 2021[66]. - The company achieved a 100% IND application approval rate, assisting 17 projects in obtaining clinical trial approvals, including 15 from China's NMPA and 8 from the US FDA[60]. Business Strategy and Operations - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5]. - The company has identified various risks including core technology loss, management personnel turnover, and insufficient working capital for expansion[4]. - The company is focused on developing new technologies and products, particularly in the biopharmaceutical sector[18]. - The company has a strategic plan to expand its market presence and enhance its research capabilities[18]. - The company decided to divest its prebiotic business to focus on CRO/CDMO services, completing the sale of Quantum High-Tech (Guangdong) Bio Co., Ltd. on June 9, 2022[39]. - The company aims to become a global leader in pharmaceutical health innovation services, emphasizing technology and scientific development[40]. - The company is expanding its capabilities in large molecule drug development with new platforms and facilities to meet growing demand[51]. - The company is exploring market expansion opportunities, particularly in emerging markets, to increase its revenue streams[130]. Research and Development - The company has developed advanced platforms for drug discovery, including CRISPR target validation and a gene-encoded compound library, enhancing early drug development efficiency[61]. - The company plans to increase its R&D budget by 30% in the upcoming year, focusing on innovative therapies[175]. - The company is investing heavily in R&D, with a budget allocation of 150 million for new technologies and product development[194]. - The company has established partnerships with three leading universities to foster research collaboration and innovation[176]. Risk Management - The company reported a significant decline in service demand, which poses risks to its operations and growth potential[4]. - The company faces risks related to declining demand for pharmaceutical R&D services, which could significantly impact its business[107]. - The company is at risk of losing key scientific and management personnel, which could adversely affect its operations and service quality[107]. - The company acknowledges the risk of new technology development failures and plans to invest in R&D and consider acquisitions to strengthen its technological capabilities[107]. - The company is subject to strict regulatory requirements in various countries, and non-compliance could lead to significant penalties and operational disruptions[108]. Governance and Management - The company has a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and protection of shareholder rights[115]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements[116]. - The company has established an internal control system to manage risks and ensure the achievement of operational goals[117]. - The company maintains transparency in information disclosure, ensuring all shareholders have equal access to information[118]. - The company experienced changes in its executive team, including the resignation of the CEO in April 2023 and the CFO in January 2023[124]. - The company has a diverse board with members holding extensive experience in pharmaceuticals and finance, including independent directors with backgrounds in international business and academia[127][131]. Environmental Responsibility - The company invested a total of ¥10,719,739.53 in environmental governance and protection during the reporting period[182]. - The company paid an environmental protection tax of ¥34,563.62 in the reporting period[182]. - The company has established hazardous waste temporary storage warehouses with protective measures to collect hazardous waste[179]. - The company conducts regular monitoring of wastewater and waste gas, ensuring compliance with environmental standards[180]. - The company has implemented measures to reduce carbon emissions, although specific details were not provided[182]. Shareholder Relations - The company did not distribute cash dividends for the 2022 fiscal year, nor did it issue bonus shares or increase capital through capital reserves[161]. - The total remuneration for directors, supervisors, and senior management in 2022 was CNY 12.7963 million[142]. - The company’s management compensation is determined based on profitability and individual responsibilities[142]. - The company aims to create long-term investment value for shareholders while ensuring compliance with profit distribution principles[161].
睿智医药(300149) - 2023 Q1 - 季度财报
2023-04-26 16:00
Financial Performance - The company's revenue for Q1 2023 was ¥268,658,644.91, a decrease of 30.45% compared to ¥386,301,922.70 in the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was a loss of ¥28,566,911.66, representing a decline of 401.63% from a profit of ¥9,470,996.67 in Q1 2022[4] - The basic and diluted earnings per share for Q1 2023 were both -¥0.0574, a decline of 402.11% from ¥0.0190 in Q1 2022[4] - Total operating revenue for Q1 2023 was CNY 268,658,644.91, a decrease of 30.5% compared to CNY 386,301,922.70 in the same period last year[18] - Net profit for Q1 2023 was a loss of CNY 28,595,596.14, compared to a profit of CNY 9,416,742.22 in Q1 2022, marking a significant decline[19] - Earnings per share for Q1 2023 was CNY -0.0574, compared to CNY 0.0190 in the same quarter last year[20] Cash Flow - The net cash flow from operating activities was -¥20,654,400.58, a decrease of 159.11% compared to ¥34,944,776.30 in the previous year[4] - The company reported a net cash outflow from operating activities of CNY -20,654,400.58, contrasting with a net inflow of CNY 34,944,776.30 in the previous year[21] - Cash flow from investing activities showed a net inflow of ¥215,815,097.92, a significant increase of 663.05% compared to -¥38,329,695.69 in the previous year[8] - The net cash flow from investment activities was 215,815,097.92 CNY, compared to a negative cash flow of -38,329,695.69 CNY in the previous period[23] - Cash inflow from financing activities totaled 30,000,000.00 CNY, while cash outflow was 299,984,196.03 CNY, resulting in a net cash flow of -269,984,196.03 CNY[23] - The company incurred a cash outflow of 288,702,550.13 CNY for debt repayment during the financing activities[23] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,482,725,233.96, down 8.92% from ¥3,823,897,141.71 at the end of the previous year[4] - The total liabilities decreased to CNY 1,130,773,989.50 from CNY 1,437,935,834.66, reflecting a reduction of approximately 21.3%[16] - Total current assets decreased to ¥869,398,720.68 from ¥1,280,359,412.36, representing a decline of about 32%[15] - Total current liabilities decreased to ¥588,480,406.09 from ¥732,030,937.52, a decline of approximately 19.6%[15] - Short-term borrowings decreased to ¥95,022,611.08 from ¥115,022,611.12, a decrease of about 17.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,692[9] - The largest shareholder, Beihai Baben Venture Capital Co., Ltd., holds 13.69% of shares, totaling 68,441,800 shares[9] Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥4,101,157.00 for the period[5] - Research and development expenses for Q1 2023 were CNY 20,950,769.76, down 26.1% from CNY 28,398,046.08 in the previous year[18] - The company recorded investment income of CNY 3,280,955.00, significantly higher than CNY 440,243.17 in Q1 2022[19] - Other comprehensive income after tax for Q1 2023 was CNY -5,414,466.45, compared to CNY -858,641.86 in the same period last year[20] Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[10] Audit Status - The first quarter report was not audited[24]
睿智医药(300149) - 2015年7月3日投资者关系活动记录表
2022-12-08 03:18
Group 1: Probiotics and Prebiotics - Probiotics are beneficial bacteria, represented by bifidobacteria, that promote nutrient absorption, enhance immunity, and prevent gastrointestinal issues [2] - Prebiotics serve as food for probiotics, primarily consisting of functional oligosaccharides, which help optimize gut flora by promoting the growth of beneficial bacteria [3] Group 2: Industry Outlook - The prebiotic industry is still in its early development stage, with vast potential for application in food, health products, and pharmaceuticals, requiring collaboration among industry players to explore opportunities [3] - The company expresses confidence in the future prospects of the prebiotic industry [3] Group 3: Business Model Transition - The company is transitioning from a B2B to a B2C model, facing challenges such as lack of experience in terminal product sales, team building, and resource acquisition [4] - Current performance relies heavily on B2B business, necessitating a strategic shift to adapt to B2C demands [4] Group 4: Market Opportunities - Collaboration with Weichuang Group aims to leverage its influence in the elderly market, which is significant due to the aging population in China [4] - The elderly demographic shows a critical need for increasing beneficial gut bacteria, making them a primary target for the company's products [4] Group 5: Future Collaborations and Investments - The company is exploring additional partnerships beyond Weichuang, with the success of current collaborations serving as a model for future endeavors [5] - An industrial merger and acquisition fund has been established, and the company is actively seeking suitable targets for investment [5]
睿智医药(300149) - 2015年6月17日投资者关系活动记录表
2022-12-07 08:24
Group 1: Market Potential - The elderly market in China is significant due to the aging population, presenting a promising market outlook [3] - As people age, beneficial gut bacteria decrease, with only 5% beneficial bacteria in the elderly compared to 95% harmful bacteria in infants, indicating a high demand for products like Aliguo among seniors [3] Group 2: Business Strategy - The company has recently partnered with Weichuang Group to leverage its influence and sales channels targeting the elderly [2][3] - The transition from B2B to B2C is challenging due to a lack of experience, resources, and established sales channels, which hinders rapid growth of Aliguo sales [4] Group 3: Product Development - There are currently no plans to launch a series of products targeting different demographics; the focus is on developing a new product, "Aliguo No. 9," in collaboration with Weichuang Group [5] - The company is actively pursuing overseas business primarily in the B2B sector, which requires significant time for development and market research [5]
睿智医药(300149) - 2018年1月18日投资者关系活动记录表
2022-12-04 10:26
Group 1: Investor Relations Activity - Quantum High-Tech conducted an investor relations activity on January 18, 2018, involving specific object research and discussions with various securities firms [2][3][4] - Participants included representatives from multiple securities firms such as Guotai Junan, Minsheng Securities, and others [2][3] Group 2: Acquisition of Ruizhi Chemical - Quantum High-Tech is planning to acquire 90% of Ruizhi Chemical's shares, discussing the transaction details and business operations during the meeting [4][5] - The company is considering renaming Ruizhi Chemical to Ruizhi Biology due to its significant business in biological research and development [4] Group 3: Business Development and Strategy - The biological business has been a highlight over the past three to four years, with a growing market share for biological drugs globally [4][6] - Ruizhi Chemical's CDMO department currently employs nearly 200 people, indicating a need for further recruitment and talent retention strategies [4][5] - The company aims to enhance its capabilities in the CDMO sector, focusing on both domestic and international markets by 2019 [6] Group 4: Future Plans and Market Position - Post-acquisition, the board of Ruizhi Chemical will include three directors appointed by Quantum High-Tech, maintaining the existing management structure while expanding talent [5][6] - The company plans to balance the development of its CRO and CMO businesses, with a focus on the growing biological drug sector [6]
睿智医药(300149) - 2018年11月6日投资者关系活动记录表
2022-12-03 09:08
Group 1: Company Overview and Investor Relations - Quantum Bio (China) Biotech Co., Ltd. is actively engaging with investors and stakeholders to discuss its business strategies and performance [1] - The investor relations activity took place on November 6, 2018, in Shanghai, attended by various investment firms and analysts [1] Group 2: Employee Dynamics and Recruitment - Employee turnover is primarily among mid-level staff, with high-level positions remaining stable; recruitment pressure has increased due to the rise of innovative drug companies [2] - The company aims to provide a platform for scientists to showcase their talents, enhancing employee retention and motivation through various incentives, including stock options [2] Group 3: Client Development and Market Strategy - The company is focusing on developing relationships with larger clients, although this strategy has both advantages and disadvantages; losing a large client can significantly impact revenue [2] - Small clients provide a diversified income source, and many have the potential to grow, leading to increased business opportunities for the company [2] Group 4: CDMO and CMO Business Development - The large molecule CDMO facility in Qidong is expected to commence production in early 2020, capable of handling clinical phase III to commercial production [3] - The current capacity for large molecule CDMO is constrained, but the team is confident in scaling up production based on client demand [3] Group 5: Market Position and Competitive Landscape - The company acknowledges that there is a significant gap in production capacity between domestic and international markets, with domestic clients often preferring to invest in their own facilities [4] - The CRO business is primarily focused on oncology, immunotherapy, and central nervous system diseases, with plans to enhance capabilities in both small and large molecule production [4] Group 6: Future Growth and Strategic Initiatives - The company is pursuing a refinancing plan to strengthen its CMO business and is actively working on integrating technology through mergers and acquisitions [4] - The micro-ecological health business is expected to grow significantly, driven by increasing consumer demand for functional foods and the company's technological advancements [4]